The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy

NCT00518817 | Unknown

• 1 other identifier: Thrasher
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This study will have significant impact on muscular dystrophy patients as it promotes early screening for heart disease. With early identification, beneficial medical therapy can be started sooner, resulting in restoring and maintaining normal heart function. This is critical to the survival of these patients. We have reported previously that heart failure in all patients may have common mechanisms, the "final common pathway". Heart failure is a significant health problem with 5 million people in the US carrying the diagnosis and accounting for 12-15 million office visits and 6.5 million hospital days per year. The number of deaths from heart failure continues to increase. The data from this study could impact patients worldwide with heart failure by offering new insight into an ever-growing disease population and lead to significant changes in how they are currently treated.

Conditions

Muscular Dystrophy; Dilated Cardiomyopathy; Heart Failure

Keywords

Dystrophy; Cardiomyopathy

Eligibility Criteria

• Age: 1 Month - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients with the diagnosis of muscular dystrophy.

You may not qualify if:

• Patients that do not carry the diagnosis of muscular dystrophy.

Sponsors & Collaborators

• Baylor College of Medicine: lead

Study Sites (1)

Texas Children's Hospital

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Muscular Dystrophies; Cardiomyopathy, Dilated; Heart Failure; Cardiomyopathies

Condition Hierarchy (Ancestors)

Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiomegaly; Heart Diseases; Cardiovascular Diseases; Laminopathies

Study Officials

• John L Jefferies, MD

  Baylor College of Medicine

  PRINCIPAL INVESTIGATOR

• Jeffrey A Towbin, MD

  Baylor College of Medicine

  STUDY DIRECTOR

Central Study Contacts

Andres Menesses-Diaz, MD

CONTACT

832-826-5600; diegom@bcm.tmc.edu

Study Design

• Study Type: observational
• Observational Model: DEFINED POPULATION
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: August 17, 2007
• First Posted: August 21, 2007
• Study Start: August 1, 2007
• Study Completion: August 1, 2009
• Last Updated: August 21, 2007

Record last verified: 2007-08

Locations

US (1)